Literature DB >> 31909413

Another layer of immune complication in glioblastoma: inducible co-stimulator and its ligand.

Masaki Terabe1, Mark R Gilbert1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2020        PMID： 31909413      PMCID： PMC7058441          DOI： 10.1093/neuonc/noaa001

Source DB:  PubMed          Journal:  Neuro Oncol        ISSN： 1522-8517            Impact factor:   12.300


× No keyword cloud information.
  8 in total

Review 1.  The future of immune checkpoint therapy.

Authors:  Padmanee Sharma; James P Allison
Journal:  Science       Date:  2015-04-03       Impact factor: 47.728

2.  Long-Term Survival of Patients With Melanoma With Active Brain Metastases Treated With Pembrolizumab on a Phase II Trial.

Authors:  Harriet M Kluger; Veronica Chiang; Amit Mahajan; Christopher R Zito; Mario Sznol; Thuy Tran; Sarah A Weiss; Justine V Cohen; James Yu; Upendra Hegde; Elizabeth Perrotti; Gail Anderson; Amanda Ralabate; Yuval Kluger; Wei Wei; Sarah B Goldberg; Lucia B Jilaveanu
Journal:  J Clin Oncol       Date:  2018-11-08       Impact factor: 44.544

3.  Immune and genomic correlates of response to anti-PD-1 immunotherapy in glioblastoma.

Authors:  Junfei Zhao; Andrew X Chen; Robyn D Gartrell; Andrew M Silverman; Luis Aparicio; Tim Chu; Darius Bordbar; David Shan; Jorge Samanamud; Aayushi Mahajan; Ioan Filip; Rose Orenbuch; Morgan Goetz; Jonathan T Yamaguchi; Michael Cloney; Craig Horbinski; Rimas V Lukas; Jeffrey Raizer; Ali I Rae; Jinzhou Yuan; Peter Canoll; Jeffrey N Bruce; Yvonne M Saenger; Peter Sims; Fabio M Iwamoto; Adam M Sonabend; Raul Rabadan
Journal:  Nat Med       Date:  2019-02-11       Impact factor: 53.440

Review 4.  Inducible Co-Stimulator (ICOS) as a potential therapeutic target for anti-cancer therapy.

Authors:  Florent Amatore; Laurent Gorvel; Daniel Olive
Journal:  Expert Opin Ther Targets       Date:  2018-03-01       Impact factor: 6.902

5.  ICOSLG-mediated regulatory T-cell expansion and IL-10 production promote progression of glioblastoma.

Authors:  Ryoichi Iwata; Joo Hyoung Lee; Mikio Hayashi; Umberto Dianzani; Kohei Ofune; Masato Maruyama; Souichi Oe; Tomoki Ito; Tetsuo Hashiba; Kunikazu Yoshimura; Masahiro Nonaka; Yosuke Nakano; Lyse Norian; Ichiro Nakano; Akio Asai
Journal:  Neuro Oncol       Date:  2020-03-05       Impact factor: 12.300

6.  Toward better early-phase brain tumor clinical trials: a reappraisal of current methods and proposals for future strategies.

Authors:  Frederick F Lang; Mark R Gilbert; Vinay K Puduvalli; Jeffrey Weinberg; Victor A Levin; W K Alfred Yung; Raymond Sawaya; Gregory N Fuller; Charles A Conrad
Journal:  Neuro Oncol       Date:  2002-10       Impact factor: 12.300

7.  First results on survival from a large Phase 3 clinical trial of an autologous dendritic cell vaccine in newly diagnosed glioblastoma.

Authors:  Linda M Liau; Keyoumars Ashkan; David D Tran; Jian L Campian; John E Trusheim; Charles S Cobbs; Jason A Heth; Michael Salacz; Sarah Taylor; Stacy D D'Andre; Fabio M Iwamoto; Edward J Dropcho; Yaron A Moshel; Kevin A Walter; Clement P Pillainayagam; Robert Aiken; Rekha Chaudhary; Samuel A Goldlust; Daniela A Bota; Paul Duic; Jai Grewal; Heinrich Elinzano; Steven A Toms; Kevin O Lillehei; Tom Mikkelsen; Tobias Walbert; Steven R Abram; Andrew J Brenner; Steven Brem; Matthew G Ewend; Simon Khagi; Jana Portnow; Lyndon J Kim; William G Loudon; Reid C Thompson; David E Avigan; Karen L Fink; Francois J Geoffroy; Scott Lindhorst; Jose Lutzky; Andrew E Sloan; Gabriele Schackert; Dietmar Krex; Hans-Jorg Meisel; Julian Wu; Raphael P Davis; Christopher Duma; Arnold B Etame; David Mathieu; Santosh Kesari; David Piccioni; Manfred Westphal; David S Baskin; Pamela Z New; Michel Lacroix; Sven-Axel May; Timothy J Pluard; Victor Tse; Richard M Green; John L Villano; Michael Pearlman; Kevin Petrecca; Michael Schulder; Lynne P Taylor; Anthony E Maida; Robert M Prins; Timothy F Cloughesy; Paul Mulholland; Marnix L Bosch
Journal:  J Transl Med       Date:  2018-05-29       Impact factor: 5.531

8.  Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastoma.

Authors:  Timothy F Cloughesy; Aaron Y Mochizuki; Joey R Orpilla; Willy Hugo; Alexander H Lee; Tom B Davidson; Anthony C Wang; Benjamin M Ellingson; Julie A Rytlewski; Catherine M Sanders; Eric S Kawaguchi; Lin Du; Gang Li; William H Yong; Sarah C Gaffey; Adam L Cohen; Ingo K Mellinghoff; Eudocia Q Lee; David A Reardon; Barbara J O'Brien; Nicholas A Butowski; Phioanh L Nghiemphu; Jennifer L Clarke; Isabel C Arrillaga-Romany; Howard Colman; Thomas J Kaley; John F de Groot; Linda M Liau; Patrick Y Wen; Robert M Prins
Journal:  Nat Med       Date:  2019-02-11       Impact factor: 53.440
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.